Attached files
| file | filename |
|---|---|
| EX-10.15 - EX-10.15 - Aligos Therapeutics, Inc. | d166948dex1015.htm |
| EX-5.1 - EX-5.1 - Aligos Therapeutics, Inc. | d166948dex51.htm |
| EX-1.1 - EX-1.1 - Aligos Therapeutics, Inc. | d166948dex11.htm |
| S-1 - S-1 - Aligos Therapeutics, Inc. | d166948ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-1) and related Prospectus of Aligos Therapeutics, Inc. for the registration of its common stock and to the incorporation by reference therein of our report dated March 23, 2021, with respect to the consolidated financial statements of Aligos Therapeutics, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2020, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Redwood City, California
June 28, 2021